MOLOGEN AG: Updated data on renal cancer therapy MGN1601 with further improved results
• Median overall survival now over 16 months
• Presentation at the ESMO Meeting in Vienna
Berlin, October 1, 2012 – Updated data on the overall survival of patients participating in the ASET study was presented within the framework of a scientific poster at this year’s meeting of the European Society for Medical Oncology (ESMO). The clinical study with the renal cancer therapy MGN1601 has progressed further and now shows a median overall survival in the PP group of over 16 months.
MOLOGEN AG: Detailed study results on colorectal cancer therapy with MGN1703 presented at the ESMO meeting
Berlin, October 1, 2012 – At the meeting of the European Society for Medical Oncology (ESMO) detailed results for the colorectal cancer study with the DNA immunomodulator MGN1703 as maintenance therapy were presented today for the first time to an expert audience of clinical oncologists and cancer researchers. This immunomodulator MGN1703 is the first candidate of a whole new class of substances in colorectal cancer which could now be tested as efficacious in a randomized study.
About MOLOGEN AG
MOLOGEN AG, a German biopharmaceutical company with headquarters in
Berlin specializes in the research and development of innovative
medications on the basis of DNA structures. The activities focus on
numerous product developments which are relevant to the immune
system; on the one hand vaccines against infectious diseases and on
the other hand cancer medications. MOLOGEN AG is globally one of
the few biotechnology companies with well tolerated DNA-based
cancer treatment in the clinical development phase.
The stocks of MOLOGEN AG (ISIN DE0006637200) are listed in the Prime Standard of the German stock exchange.
www.mologen.com
Memberships in associations:
Biotechnologieverbund Berlin-Brandenburg (bbb) e.V. | BIO
Deutschland e.V. | DECHEMA - Society for chemical technology and
biotechnology e.V. | German industrial association of biotechnology
(DIB) | Association for the Promotion of Science and Humanities in
Germany | Association of German biotechnology companies (VBU) |
Association of researching manufacturers of pharmaceuticals e.V.
(VFA) | Association of the chemical industry e.V. (VCI)
MIDGE®, dSLIM® and MOLOGEN® are registered trademarks of MOLOGEN AG.
MOLOGEN AG
PRESS SERVICE:
Prof. Peter W. Huebner
Head of Corporate Communications
Tel: +49 - 30 - 84 17 88 - 38
Tel: +49 - 30 - 84 17 88 - 50
huebner@mologen.com
INVESTOR RELATIONS:
Joerg Petrass
Tel: +49 - 30 - 84 17 88 - 13
Tel: +49 - 30 - 84 17 88 - 50
investor@mologen.com
External Investor Relations:
Kirchhoff Consult AG
Sebastian Bucher
T: +49 - 40 - 60 91 86 - 18
F: +49 - 40 - 60 91 86 -16
sebastian.bucher@kirchhoff.de
Note about risk for future predictions
Certain information in this report contains forward-looking
statements or the corresponding statements with negation or
versions deviating from this or comparable terminology. These are
described as forward-looking statements. In addition, all of the
information given here that refers to planned or future results of
business areas, key financial figures, developments of the
financial situation or other financial figures or statistical data,
is to be understood as such forward-looking statements. The company
points out to investors that they should not rely on these
forward-looking statements as predictions about actual future
events. The company is not obligated and refuses to accept any
liability for the forward-looking statements and has no obligation
to update such statements in order to accurately reflect the
current situation.
Posted: October 2012
